| New from NCI |
| Video—T-Cell Transfer Therapy |
 |
|
How is the immune system used to fight cancer? This video explains one type of immunotherapy that boosts the immune system's ability to rid the body of cancer. |
| Test Helps Identify Thyroid Nodules That Don’t Require Surgery |
 |
|
The test, which measures gene changes in thyroid tissue samples, was developed to prevent unnecessary thyroid surgeries. |
Primary Bone Cancer
Primary bone cancer is cancer that starts in the bone. Learn about bone cancer statistics, the main types of primary bone cancer, possible causes, treatment, and the side effects of treatment. |
| Advance in Treatment for Chronic Lymphocytic Leukemia |
 |
|
A clinical trial showed that ibrutinib plus rituximab is better than the standard treatment for patients aged 70 and younger with untreated chronic lymphocytic leukemia. |
Can Topical Drugs Help Prevent Breast Cancer?
Researchers are testing whether a topical gel form of the drug tamoxifen that women apply to their breasts helps prevent breast cancer as well as oral tamoxifen but with fewer side effects. |
Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival
In an early-phase clinical trial, a drug combination that targets tumors with a specific genetic change improved how long some patients with biliary tract cancer or adenocarcinoma of the small intestine lived. |
Secondhand Smoke and Cancer
Secondhand smoke is smoke that comes from the burning of a tobacco product and that is exhaled by smokers. Learn more about secondhand smoke and the problems it can cause on this recently updated page.
|
| Drug Information Updates |
Pembrolizumab
We’ve updated our drug summary on pembrolizumab (Keytruda) with a recent Food and Drug Administration (FDA) approval. The drug is now approved to treat hepatocellular carcinoma in patients who have been treated with sorafenib. Hepatocellular carcinoma is the most common type of liver cancer. |
Venetoclax
We’ve updated our drug summary on venetoclax (Venclexta) with a recent FDA approval. The drug is now approved to treat newly diagnosed acute myeloid leukemia in patients aged 75 and older or adults who cannot be treated with intensive induction chemotherapy. It is given with either azacitidine, decitabine, or low-dose cytarabine. |
